162 related articles for article (PubMed ID: 21247217)
1. Binding of a C-end rule peptide to the neuropilin-1 receptor: a molecular modeling approach.
Haspel N; Zanuy D; Nussinov R; Teesalu T; Ruoslahti E; Aleman C
Biochemistry; 2011 Mar; 50(10):1755-62. PubMed ID: 21247217
[TBL] [Abstract][Full Text] [Related]
2. Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor.
Zanuy D; Kotla R; Nussinov R; Teesalu T; Sugahara KN; Alemán C; Haspel N
J Struct Biol; 2013 May; 182(2):78-86. PubMed ID: 23462097
[TBL] [Abstract][Full Text] [Related]
3. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.
Teesalu T; Sugahara KN; Kotamraju VR; Ruoslahti E
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16157-62. PubMed ID: 19805273
[TBL] [Abstract][Full Text] [Related]
4. tLyp-1: A peptide suitable to target NRP-1 receptor.
Larue L; Kenzhebayeva B; Al-Thiabat MG; Jouan-Hureaux V; Mohd-Gazzali A; Wahab HA; Boura C; Yeligbayeva G; Nakan U; Frochot C; Acherar S
Bioorg Chem; 2023 Jan; 130():106200. PubMed ID: 36332316
[TBL] [Abstract][Full Text] [Related]
5. Does Cysteine Rule (CysR) Complete the CendR Principle? Increase in Affinity of Peptide Ligands for NRP-1 Through the Presence of N-Terminal Cysteine.
Puszko AK; Sosnowski P; Raynaud F; Hermine O; Hopfgartner G; Lepelletier Y; Misicka A
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32183142
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin Fc-Fused Peptide without C-Terminal Arg or Lys Residue Augments Neuropilin-1-Dependent Tumor Vascular Permeability.
Baek DS; Kim JH; Kim YJ; Kim YS
Mol Pharm; 2018 Feb; 15(2):394-402. PubMed ID: 29232521
[TBL] [Abstract][Full Text] [Related]
7. Modeling of a C-end rule peptide adsorbed onto gold nanoparticles.
Triguero J; Flores-Ortega A; Zanuy D; Alemán C
J Pept Sci; 2018 Jan; 24(1):. PubMed ID: 29231280
[TBL] [Abstract][Full Text] [Related]
8. Molecular modelling, synthesis and biological evaluation of peptide inhibitors as anti-angiogenic agent targeting neuropilin-1 for anticancer application.
Kamarulzaman EE; Vanderesse R; Gazzali AM; Barberi-Heyob M; Boura C; Frochot C; Shawkataly O; Aubry A; Wahab HA
J Biomol Struct Dyn; 2017 Jan; 35(1):26-45. PubMed ID: 26766582
[TBL] [Abstract][Full Text] [Related]
9. Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.
Paoli EE; Ingham ES; Zhang H; Mahakian LM; Fite BZ; Gagnon MK; Tam S; Kheirolomoom A; Cardiff RD; Ferrara KW
J Control Release; 2014 Mar; 178():108-17. PubMed ID: 24434424
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for ligand and heparin binding to neuropilin B domains.
Vander Kooi CW; Jusino MA; Perman B; Neau DB; Bellamy HD; Leahy DJ
Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6152-7. PubMed ID: 17405859
[TBL] [Abstract][Full Text] [Related]
11. Sugar-based peptidomimetics as potential inhibitors of the vascular endothelium growth factor binding to neuropilin-1.
Novoa A; Pellegrini-Moïse N; Bechet D; Barberi-Heyob M; Chapleur Y
Bioorg Med Chem; 2010 May; 18(9):3285-98. PubMed ID: 20363638
[TBL] [Abstract][Full Text] [Related]
12. Effect of C-terminal sequence on competitive semaphorin binding to neuropilin-1.
Parker MW; Linkugel AD; Vander Kooi CW
J Mol Biol; 2013 Nov; 425(22):4405-14. PubMed ID: 23871893
[TBL] [Abstract][Full Text] [Related]
13. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex.
Starzec A; Ladam P; Vassy R; Badache S; Bouchemal N; Navaza A; du Penhoat CH; Perret GY
Peptides; 2007 Dec; 28(12):2397-402. PubMed ID: 17983687
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship study of tetrapeptide inhibitors of the Vascular Endothelial Growth Factor A binding to Neuropilin-1.
Tymecka D; Lipiński PFJ; Fedorczyk B; Puszko A; Wileńska B; Perret GY; Misicka A
Peptides; 2017 Aug; 94():25-32. PubMed ID: 28627371
[TBL] [Abstract][Full Text] [Related]
15. N-terminal modification of VEGF-A C terminus-derived peptides delineates structural features involved in neuropilin-1 binding and functional activity.
Jia H; Aqil R; Cheng L; Chapman C; Shaikh S; Jarvis A; Chan AW; Hartzoulakis B; Evans IM; Frolov A; Martin J; Frankel P; Djordevic S; Zachary IC; Selwood DL
Chembiochem; 2014 May; 15(8):1161-70. PubMed ID: 24771685
[TBL] [Abstract][Full Text] [Related]
16. Peptides Derived from Vascular Endothelial Growth Factor B Show Potent Binding to Neuropilin-1.
Mota F; Yelland T; Hutton JA; Parker J; Patsiarika A; Chan AWE; O'Leary A; Fotinou C; Martin JF; Zachary IC; Djordjevic S; Frankel P; Selwood DL
Chembiochem; 2022 Jan; 23(1):e202100463. PubMed ID: 34647407
[TBL] [Abstract][Full Text] [Related]
17. Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa.
Pemmari T; Ivanova L; May U; Lingasamy P; Tobi A; Pasternack A; Prince S; Ritvos O; Makkapati S; Teesalu T; Cairo MS; Järvinen TAH; Liao Y
Mol Ther; 2020 Aug; 28(8):1833-1845. PubMed ID: 32497513
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1.
Parker MW; Xu P; Li X; Vander Kooi CW
J Biol Chem; 2012 Mar; 287(14):11082-9. PubMed ID: 22318724
[TBL] [Abstract][Full Text] [Related]
19. SPECT and near-infrared fluorescence imaging of breast cancer with a neuropilin-1-targeting peptide.
Feng GK; Liu RB; Zhang MQ; Ye XX; Zhong Q; Xia YF; Li MZ; Wang J; Song EW; Zhang X; Wu ZZ; Zeng MS
J Control Release; 2014 Oct; 192():236-42. PubMed ID: 25058570
[TBL] [Abstract][Full Text] [Related]
20. Identification of Four New Chemical Series of Small Drug-Like Natural Products as Potential Neuropilin-1 Inhibitors by Structure-Based Virtual Screening: Pharmacophore-Based Molecular Docking and Dynamics Simulation.
Sabki A; Khelifi L; Kameli A; Baali S
Chem Biodivers; 2023 Mar; 20(3):e202200933. PubMed ID: 36799050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
